MGMAR: Metal-Guided Metal Artifact Reduction for X-ray Computed Tomography
This addresses diagnostic quality degradation in medical imaging for patients with metallic implants, representing a strong domain-specific advance.
The paper tackles metal artifact reduction in X-ray CT scans by proposing MGMAR, a method that uses metal-guided information and implicit neural representations to improve reconstruction, achieving a state-of-the-art average score of 0.89 on clinical test cases.
An X-ray computed tomography (CT), metal artifact reduction (MAR) remains a major challenge because metallic implants violate standard CT forward-model assumptions, producing severe streaking and shadowing artifacts that degrade diagnostic quality. We propose MGMAR, a metal-guided MAR method that explicitly leverages metal-related information throughout the reconstruction pipeline. MGMAR first generates a high-quality prior image by training a conditioned implicit neural representation (INR) using metal-unaffected projections, and then incorporates this prior into a normalized MAR (NMAR) framework for projection completion. To improve robustness under severe metal corruption, we pretrain the encoder-conditioned INR on paired metal-corrupted and artifact-free CT images, thereby embedding data-driven prior knowledge into the INR parameter space. This prior-embedded initialization reduces sensitivity to random initialization and accelerates convergence during measurement-specific refinement. The encoder takes a metal-corrupted reconstruction together with a recursively constructed metal artifact image, enabling the latent field to capture metal-dependent global artifact patterns. After projection completion using the INR prior, we further suppress residual artifacts using a metal-conditioned correction network, where the metal mask modulates intermediate features via adaptive instance normalization to target metal-dependent secondary artifacts while preserving anatomical structures. Experiments on the public AAPM-MAR benchmark demonstrate that MGMAR achieves state-of-the-art performance, attaining an average final score of 0.89 on 29 clinical test cases.